Clark Estates Inc. NY Cuts Position in IQVIA Holdings Inc. $IQV

Clark Estates Inc. NY lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 25.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 115,200 shares of the medical research company’s stock after selling 40,000 shares during the quarter. IQVIA accounts for 5.0% of Clark Estates Inc. NY’s holdings, making the stock its 2nd biggest position. Clark Estates Inc. NY’s holdings in IQVIA were worth $21,881,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Physician Wealth Advisors Inc. boosted its holdings in IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after purchasing an additional 134 shares during the last quarter. Westside Investment Management Inc. boosted its stake in shares of IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after buying an additional 101 shares during the last quarter. Atlantic Union Bankshares Corp acquired a new position in shares of IQVIA during the 3rd quarter worth about $36,000. Root Financial Partners LLC bought a new position in shares of IQVIA in the 3rd quarter valued at about $43,000. Finally, Hantz Financial Services Inc. increased its position in shares of IQVIA by 92.0% in the third quarter. Hantz Financial Services Inc. now owns 240 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 115 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

IQV has been the subject of a number of analyst reports. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday. Evercore reissued an “outperform” rating and issued a $225.00 target price on shares of IQVIA in a research note on Thursday, February 5th. JPMorgan Chase & Co. lowered their target price on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a report on Friday, February 6th. TD Cowen increased their price target on shares of IQVIA from $215.00 to $245.00 and gave the company a “hold” rating in a research note on Thursday, January 22nd. Finally, BMO Capital Markets set a $250.00 price objective on shares of IQVIA in a research note on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $235.20.

IQVIA Trading Down 2.2%

IQV stock opened at $165.63 on Monday. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The stock has a market cap of $28.11 billion, a price-to-earnings ratio of 21.07, a price-to-earnings-growth ratio of 1.60 and a beta of 1.37. The company has a fifty day moving average price of $217.61 and a two-hundred day moving average price of $208.66. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company had revenue of $4.36 billion during the quarter, compared to analysts’ expectations of $4.24 billion. During the same quarter last year, the company posted $3.12 EPS. IQVIA’s quarterly revenue was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.